FGFR1 is Essential for Prostate Cancer Progression and Metastasis

Overview

Journal Cancer Res

Specialty Oncology

Date 2013 Apr 12

PMID 23576558

Citations 49

Authors

Feng Yang

Yongyou Zhang

Steven J Ressler

Michael M Ittmann

Gustavo E Ayala

Truong D Dang

Fen Wang

David R Rowley

Affiliations

Soon will be listed here.

Abstract

The fibroblast growth factor receptor 1 (FGFR1) is ectopically expressed in prostate carcinoma cells, but its functional contributions are undefined. In this study, we report the evaluation of a tissue-specific conditional deletion mutant generated in an ARR2PBi(Pbsn)-Cre/TRAMP/fgfr1(loxP/loxP) transgenic mouse model of prostate cancer. Mice lacking fgfr1, in prostate cells developed smaller tumors that also included distinct cancer foci still expressing fgfr1 indicating focal escape from gene excision. Tumors with confirmed fgfr1 deletion exhibited increased foci of early, well-differentiated cancer and phyllodes-type tumors, and tumors that escaped fgfr1 deletion primarily exhibited a poorly differentiated phenotype. Consistent with these phenotypes, mice carrying the fgfr1 null allele survived significantly longer than those without fgfr1 deletion. Most interestingly, all metastases were primarily negative for the fgfr1 null allele, exhibited high FGFR1 expression, and a neuroendocrine phenotype regardless of fgfr1 status in the primary tumors. Together, these results suggest a critical and permissive role of ectopic FGFR1 signaling in prostate tumorigenesis and particularly in mechanisms of metastasis.

Citing Articles

Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response.

Archer M, Lin K, Kolanukuduru K, Zhang J, Ben-David R, Kotula L Am J Clin Exp Urol. 2025; 12(6):331-351.

PMID: 39839748 PMC: 11744350. DOI: 10.62347/YFRP8901.

FGFR1 governs iron homeostasis via regulating intracellular protein degradation pathways of IRP2 in prostate cancer cells.

Lin H, Lin S, Shi L, Xu G, Lin M, Li S Commun Biol. 2024; 7(1):1011.

PMID: 39154074 PMC: 11330447. DOI: 10.1038/s42003-024-06704-6.

Identification of mechanism of the oncogenic role of FGFR1 in papillary thyroid carcinoma.

Li X, Li J, Wang C, Zhang Y, Li J Eur J Histochem. 2024; 68(3).

PMID: 39037153 PMC: 11287999. DOI: 10.4081/ejh.2024.4048.

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer.

Dincman T, Karam J, Giordano A, Li H, Drusbosky L, Gourdin T Front Oncol. 2024; 13:1202277.

PMID: 38450313 PMC: 10915757. DOI: 10.3389/fonc.2023.1202277.

FGFR families: biological functions and therapeutic interventions in tumors.

Liu Q, Huang J, Yan W, Liu Z, Liu S, Fang W MedComm (2020). 2023; 4(5):e367.

PMID: 37750089 PMC: 10518040. DOI: 10.1002/mco2.367.

References

Lin Y, Liu G, Zhang Y, Hu Y, Yu K, Lin C . Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development. 2007; 134(4):723-34. DOI: 10.1242/dev.02765. View

Shappell S, Thomas G, Roberts R, Herbert R, Ittmann M, Rubin M . Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004; 64(6):2270-305. DOI: 10.1158/0008-5472.can-03-0946. View

Trokovic N, Trokovic R, Mai P, Partanen J . Fgfr1 regulates patterning of the pharyngeal region. Genes Dev. 2003; 17(1):141-53. PMC: 195961. DOI: 10.1101/gad.250703. View

Wang F, McKeehan K, Yu C, Ittmann M, McKeehan W . Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. Prostate. 2003; 58(1):1-12. DOI: 10.1002/pros.10311. View

Kaplan-Lefko P, Chen T, Ittmann M, Barrios R, Ayala G, Huss W . Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate. 2003; 55(3):219-37. DOI: 10.1002/pros.10215. View

Pirvola U, Ylikoski J, Trokovic R, Hebert J, McConnell S, Partanen J . FGFR1 is required for the development of the auditory sensory epithelium. Neuron. 2002; 35(4):671-80. DOI: 10.1016/s0896-6273(02)00824-3. View

Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D . Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002; 8(9):2912-23. View

Trokovic R, Trokovic N, Hernesniemi S, Pirvola U, Vogt Weisenhorn D, Rossant J . FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J. 2003; 22(8):1811-23. PMC: 154461. DOI: 10.1093/emboj/cdg169. View

Mosca A, Berruti A, Russo L, Torta M, Dogliotti L . The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest. 2006; 28(11 Suppl International):141-5. View

10.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

11.

Foster B, Kaplan P, Greenberg N . Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model. Prostate Cancer Prostatic Dis. 2002; 2(2):76-82. DOI: 10.1038/sj.pcan.4500297. View

12.

Memarzadeh S, Xin L, Mulholland D, Mansukhani A, Wu H, Teitell M . Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell. 2007; 12(6):572-85. PMC: 2931420. DOI: 10.1016/j.ccr.2007.11.002. View

13.

Giri D, Ropiquet F, Ittmann M . Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res. 1999; 5(5):1063-71. View

14.

Sahadevan K, Darby S, Leung H, Mathers M, Robson C, Gnanapragasam V . Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007; 213(1):82-90. DOI: 10.1002/path.2205. View

15.

Ittman M, Mansukhani A . Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol. 1997; 157(1):351-6. View

16.

Jin C, McKeehan K, Wang F . Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate. 2003; 57(2):160-4. DOI: 10.1002/pros.10283. View

17.

Acevedo V, Gangula R, Freeman K, Li R, Zhang Y, Wang F . Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007; 12(6):559-71. DOI: 10.1016/j.ccr.2007.11.004. View

18.

Greenberg N, DeMayo F, Finegold M, Medina D, Tilley W, Aspinall J . Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995; 92(8):3439-43. PMC: 42182. DOI: 10.1073/pnas.92.8.3439. View

19.

Udayakumar T, Klein R, Maliner M, Nagle R, Bowden G . Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer. 2001; 91(2):187-92. DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1023>3.3.co;2-n. View

20.

Devilard E, Bladou F, Ramuz O, Karsenty G, Dales J, Gravis G . FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer. 2006; 6:272. PMC: 1698935. DOI: 10.1186/1471-2407-6-272. View